As of November 6, 2026, Monopar Therapeutics is a publicly traded company (Nasdaq: MNPR); its largest reported holder is Janus Henderson, with 19.5% on Schedule 13G/A of November 14, 2025, then RA Capital (9.9%) (Schedule 13G/A, November 14, 2025).
Is this your company?
About to sign with, pay or invest in Monopar Therapeutics? See the free Snapshot first.
Free to see. No signup.
Is Monopar Therapeutics a real, registered company?
- Monopar Therapeutics files with the SEC under CIK 1645469 (its SEC filings).
- Its shares are listed under the ticker MNPR on Nasdaq (SEC company record).
- Incorporated in Delaware; business address in Wilmette, Illinois, as its SEC filings state.
- Court and bankruptcy records: see Before you sign or pay below.
Before you sign or pay
- Court and bankruptcy: No federal court case or bankruptcy filing found under MONOPAR THERAPEUTICS in our court records and SEC 8-K records (as of 2026-11-06).
- Ownership: 5%+ holders are reported on Schedule 13D or 13G; the latest names BlackRock (filed 2026-10-27).
Who are Monopar Therapeutics' owners and officers?
Monopar Therapeutics: incorporated in Delaware; business address in Wilmette, Illinois; industry Pharmaceutical Preparations (Schedule 13G, 2026-10-27).
| Report | Holder | Share |
|---|---|---|
| Schedule 13G, 2026-10-27 | Blackrock, Inc. | 5.03% |
| Schedule 13G/A, 2026-08-12 | Adage Capital Management, L.P. | 4.76% |
| Schedule 13G/A, 2026-08-12 | Saturn V Capital Management LP | 4.7% |
| Schedule 13G, 2026-05-15 | Saturn V Capital Management LP | 5.2% |
| Schedule 13G/A, 2026-05-13 | Adage Capital Management, L.P. | 6.23% |
| Schedule 13G/A, 2026-02-17 | Ra Capital Management, L.P. | 9.9% |
| Schedule 13G/A, 2026-02-06 | Astrazeneca PLC | 7.8% |
| Schedule 13D/A, 2026-01-30 | Tactic Pharma LLC | 4.5% |
| Schedule 13G/A, 2025-11-14 | Janus Henderson Group PLC | 19.5% |
| Schedule 13G/A, 2025-11-14 | Ra Capital Management, L.P. | 9.9% |
| Schedule 13D/A, 2025-09-24 | Tactic Pharma LLC | 7.5% |
| Schedule 13G/A, 2025-08-14 | Janus Henderson Group PLC | 19.2% |
Questions about who owns Monopar Therapeutics
Who owns Monopar Therapeutics?
On this page, 4 holders' latest ownership filings report 5% or more of Monopar Therapeutics: Janus Henderson Group PLC (19.5%, Schedule 13G/A, filed 2025-11-14), Ra Capital Management, L.P. (9.9%, Schedule 13G/A, filed 2026-02-17), Astrazeneca PLC (7.8%, Schedule 13G/A, filed 2026-02-06) and Blackrock, Inc. (5.03%, Schedule 13G, filed 2026-10-27).
Who are the largest shareholders of Monopar Therapeutics?
By the share each holder's latest filing reports, the largest holders of Monopar Therapeutics on this page are Janus Henderson Group PLC (19.5%), Ra Capital Management, L.P. (9.9%) and Astrazeneca PLC (7.8%).
When did Janus Henderson Group PLC buy into Monopar Therapeutics?
The filings give report dates, not purchase dates. The earliest filing from Janus Henderson Group PLC on this page is the Schedule 13G/A, filed 2025-08-14, reporting 19.2%; its latest, Schedule 13G/A filed 2025-11-14, reports 19.5%. That earliest filing is itself an amendment, which updates an earlier report.
Is this an audit or a full list?
Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 12 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.
Want the whole picture on Monopar Therapeutics?
Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC
A Full Report on Monopar Therapeutics: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Monopar Therapeutics covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
15 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Which insiders own Monopar Therapeutics shares?
Directors, officers and holders of 10% or more report their shares on Forms 3, 4 and 5. Each line is the latest such report, largest holding first.
- , a 10% owner: 567,580 shares (8.5% of shares outstanding), held indirectly (the form names the holder only in its footnotes) (Form 4, 2025-12-17).
- Mazar Andrew Paul: 272,026 shares (4.1% of shares outstanding), on a joint filing (Form 4, 2025-09-26).
- Tactic Pharma LLC, the chief executive and a director: 272,026 shares (4.1% of shares outstanding), on a joint filing (Form 4, 2025-09-26).
- Michael J. Brown: 272,026 shares (4.1% of shares outstanding), on a joint filing (Form 4, 2025-09-26).
- Thomas O'Halloran V: 272,026 shares (4.1% of shares outstanding), on a joint filing (Form 4, 2025-09-26).
Shares outstanding: 6,712,172 as of 2026-07-31, from the company's latest SEC cover page.
How much has Monopar Therapeutics raised?
No fundraising or offering filing from Monopar Therapeutics is on file with us.
Keep reading
More on Monopar Therapeutics and the records around it.
Monopar Therapeutics elsewhere on the record
- 5%+ stake filings Oct 2026
Companies that share a holder
- Saturn V Capital Management LP also filed stake reports on 2 other companies: Immix Biopharma, Inc. (Feb 2026), X4 Pharmaceuticals, Inc. (Feb 2026)
- RA Capital Management, L.P. also filed stake reports on 100 other companies: Climb Bio, Inc. (Nov 2026), Bambusa Therapeutics, Inc. (Nov 2026), SOLID BIOSCIENCES INC. (Nov 2026)
- JANUS HENDERSON GROUP PLC also filed stake reports on 104 other companies: SURGERY PARTNERS, INC. (Nov 2026), EYEPOINT, INC. (Sep 2026), TELEFLEX INCORPORATED (Sep 2026)
Related pages
Filings, cases and notices link to their records. A not-found line names the records searched; it is not proof of absence.
Not for employment, credit, insurance or tenancy decisions.
Cite this page
https://mentionfox.com/who-owns/monopar-therapeutics